Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3888550A

Next Previous
Drug Profile

GSK 3888550A

Alternative Names: GSK3888550A; GSK3888550A RSV maternal vaccine; RSV-MAT; RSVPreF3; Unadjuvanted RSV maternal vaccine - GSK

Latest Information Update: 03 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 15 Jan 2025 GSK completes a phase III trial in Respiratory syncytial virus infections (In adolescents, In children, Prevention, In adults) in Thailand, Taiwan, Taiwan, Philippines, South Korea, Italy, India, Honduras, Dominican Republic, Germany, Brazil, Bangladesh, Australia, USA, Canada, France, Belgium, New Zealand, Argentina, Colombia, Panama, South Africa, Finland and Spain (IM) (NCT05705440)
  • 28 Nov 2023 GlaxoSmithKline terminates a phase III trial in Respiratory syncytial virus infections (Prevention) in Brazil, Canada, Finland, India, Italy, Panama, South Africa, Spain and USA based on the recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009) (IM) (NCT04980391)
  • 11 Sep 2023 GlaxoSmithKline terminates the phase III trial in Respiratory syncytial virus infections (Prevention) in Argentina, Australia, Bangladesh, Belgium, Brazil, Canada, Colombia, Dominican Republic, Finland, France, Honduras, India, Italy, Mexico, New Zealand, Panama, Philippines, South Africa, South Korea, Spain, Taiwan, Thailand, United Kingdom and USA based on the recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009) (IM) (NCT04605159)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top